Back to Awarded Treatment Trials
Awarded Trial: 02T-135
Grant ID
02T-135
Illness
Schizophrenia
Primary Drug/Intervention
Buspirone
Primary Dosage
15mg-30mg
Secondary Drug Intervention
N/A
Secondary Dosage
N/A
Other Drug/Intervention
N/A
Other Dosage
N/A
Status
Completed
Investigator
Norman
Sample Size
18
Duration of Study Period for Each Subject
13 weeks
Outcome Measurements
SADS-L, PANSS, SANS, BPRS, AIMS, cognitive battery
Results
Eighteen patients were randomized to buspirone or placebo for 6 wks as adjunct medication. There were no significance differences between the two groups on measures of cognitive function or symptom rating.
Publication
Piskulic D, Olver JS, Maruff P, Norman TR. Treatment of cognitive dysfunction in chronic schizophrenia by augmentation of atypical antipsychotics with buspirone, a partial 5-HT1A receptor agonist. Hum Psychopharmacol. 2009 Aug;24(6):437-46.
Link
http://www.ncbi.nlm.nih.gov/pubmed/19637398
PI Name
Trevor Norman
Degree
PhD
Center
Department of Psychiatry
Institution
University of Melbourne
Address
Austin and Repatriation Medical Centre
City or Town
Heidelberg
State or Province
Victoria
Zip or Postal Code
3084
Country
Australia
Email Address
trevorrn@unimelb.edu.au